Document:

EX-10.4

 Exhibit 10.4 

VOTING AGREEMENT 
 This
VOTING AGREEMENT (this “Agreement”) is entered into as of February 12, 2016 (the “Effective Date”) by and among Atrinsic, Inc., a Delaware corporation (the “Company”), the parties listed as
stockholders of Protagenic Therapeutics, Inc. (the “Protagenic Therapeutics Stockholders”) on the signature pages hereto, and Strategic Bio Partners, LLC (“Strategic”), each such person a “Stockholder” and
collectively, the “Stockholders”. 
 W I T N E S S E T H: 

WHEREAS, as of the date hereof, each Stockholder holds and is entitled to vote (or to direct the voting of) shares of (i) common
stock, par value $0.000001 per share of the Company (the “Common Stock”), and/or (ii) shares of Series B preferred stock, par value $0.000001 per share, of the Company (the “Series B Shares”, and together with
the Common Stock, the “Voting Shares”), of the Company (such Voting Shares, together with any other Voting Shares the voting power of which is acquired by such Stockholders during the period from the date hereof through the date on
which this Agreement is terminated in accordance with its terms (such period, the “Voting Period”), are collectively referred to herein as the “Subject Shares”); 

WHEREAS, the Company has entered into an Agreement and Plan of Merger with Protagenic Therapeutics, Inc., a Delaware corporation
(“Protagenic”), pursuant to which a newly organized, wholly-owned subsidiary of the Company has merged with and into Protagenic, with Protagenic remaining as the surviving entity and a wholly-owned subsidiary of the Company (the
“Merger”); 
 WHEREAS, simultaneously with the Merger and to provide the capital required by the Company for working
capital and other purposes, the Company has offered Series B Shares to investors in a private placement transaction (the “PPO”) in compliance with Rule 506 of Regulation D of the Securities Act of 1933, as amended; 

WHEREAS, the initial closing of the PPO and the closing of the Merger have taken place as of the Effective Date; and 

WHEREAS, as an inducement to the parties’ willingness to consummate the transactions contemplated by the Merger Agreement, the
Company and the Stockholders are entering into this Agreement. 
 NOW, THEREFORE, in consideration of the mutual promises,
representations, warranties, covenants, and conditions set forth herein, the parties mutually agree as follows: 

 ARTICLE I 

DEFINITIONS 

Section 1.1 Capitalized Terms. For purposes of this Agreement, capitalized terms used and not defined herein shall have the
respective meanings ascribed to them in the Merger Agreement. 
 ARTICLE II  

VOTING AGREEMENT AND IRREVOCABLE PROXY 

Section 2.1 Agreement to Vote the Subject Shares. Each Stockholder hereby agrees that, during the Voting Period, at any duly
called meeting of the stockholders of the Company (or any adjournment or postponement thereof) or action taken by written consent in lieu of a meeting, each Stockholder shall, if a meeting is held, appear at the meeting, in person or by proxy, or
otherwise cause his Subject Shares owned at any time to be counted as present thereat for purposes of establishing a quorum, and he shall vote (or cause to be voted), in person or by proxy, all of his Subject Shares: 

(a) to ensure that the size of the Board shall be set and remain at five (5) directors unless increased by the Board;

 (b) to ensure that at each annual or special meeting of stockholders at which an election of directors is held or pursuant
to any written consent of the Stockholders, one person designated by Strategic shall be elected to the Board, which individual shall initially be Josh Silverman; 

(c) to ensure that at each annual or special meeting of stockholders at which an election of directors is held or pursuant to
any written consent of the Stockholders, four persons designated by Garo H. Armen (as long as he is an officer or director of the Company) shall be elected to the Board, which individuals shall initially be Garo H. Armen, Robert B. Stein, Khalil
Barrage and Gregory H. Ekizian; and 
 (d) to ensure that the Company files an amendment to its certificate of incorporation
to effect a one-for-15,463.7183 reverse stock split. 
 Section 2.2 Grant of Irrevocable Proxy. If requested by the Company,
each Stockholder shall appoint the Company and any designee of the Company, and each of them individually, as each Stockholder’s proxy, with full power of substitution and resubstitution, to vote during the Voting Period with respect to any and
all of the Subject Shares on the matters and in the manner specified in Section 2.1. Each Stockholder shall take such further action or execute such other instruments as may be reasonably necessary to effectuate the intent of any such
proxy. Each Stockholder affirms that any irrevocable proxy given by such Stockholder with respect to this Agreement and the transactions contemplated hereby shall be given to the Company by such Stockholder to secure the performance of the
obligations of the Stockholder under this Agreement. It is agreed that the Company (and its officers on behalf of the Company) will use the irrevocable proxy that may be granted by each Stockholder only in accordance with applicable law and only if
such Stockholder fails to comply with Section 2.1 and that, to the 

  
 -2- 

 
extent the Company (and its officers on behalf of the Company) uses any such irrevocable proxy, he will only vote the Subject Shares subject to such irrevocable proxy with respect to the matters
specified in, and in accordance with the provisions of, Section 2.1. 
 Section 2.3 Nature of Irrevocable Proxy. Any
proxy granted pursuant to Section 2.2 to the Company by the Stockholders shall be irrevocable during the term of this Agreement, shall be deemed to be coupled with an interest sufficient in law to support an irrevocable proxy and shall
revoke any and all prior proxies granted by the Stockholders. Any proxy that may be granted hereunder shall terminate upon the termination of this Agreement. 

ARTICLE III  
 COVENANTS

 Section 3.1 Subject Shares. 

(a) Each Stockholder agrees that during the Voting Period such Stockholder shall not, without the Company’s prior written
consent, grant any proxies or powers of attorney with respect to any or all of the Subject Shares or agree to vote the Subject Shares on any matter inconsistent with the terms described herein; provided, however, that in
the event a Stockholder transfers all or any portion of his Subject Shares such Stockholder shall be permitted to grant stock powers with respect to such transferred Subject Shares. 

(b) In the event of (i) a stock dividend or distribution, (ii) any change in the Subject Shares by reason of any
stock dividend or distribution, split-up, recapitalization, combination, conversion, exchange of shares or the like or (iii) the conversion of Series B Shares into Common Shares, the term “Subject Shares” shall be deemed to refer to
and include the Subject Shares as well as all such stock dividends and distributions and any securities into which or for which any or all of the Subject Shares may be changed, exchanged or converted or which are received in such transaction. 

Section 3.2 Voting Trusts. Each Stockholder agrees that it will not, nor will it permit any entity under its control to, deposit
any of such Stockholder’s Subject Shares in a voting trust or subject any of its Subject Shares to any arrangement with respect to the voting of such Subject Shares other than as provided herein. Notwithstanding the foregoing, each Stockholder
shall be permitted to transfer all or any portion of its Subject Shares to third parties. 
 ARTICLE IV  

REPRESENTATIONS AND WARRANTIES OF EACH STOCKHOLDER 

Each Stockholder hereby represents and warrants to the Company, severally, but not jointly, as follows: 

Section 4.1 Authority, etc. The Stockholder (i) if a natural person, represents that the Stockholder has reached the age of
21 and has full power and authority to execute and deliver this Agreement and all other related agreements or certificates and to carry out the provisions hereof and thereof; (ii) if a corporation, partnership, or limited liability company or

  
 -3- 

 
partnership, or association, joint stock company, trust, unincorporated organization or other entity, represents that such entity was not formed for the specific purpose of acquiring the Series B
Shares, such entity is duly organized, validly existing and in good standing under the laws of the state of its organization, the consummation of the transactions contemplated hereby is authorized by, and will not result in a violation of state law
or its charter or other organizational documents, such entity has full power and authority to execute and deliver this Agreement and all other related agreements or certificates and to carry out the provisions hereof and thereof, the execution and
delivery of this Agreement has been duly authorized by all necessary action, this Agreement has been duly executed and delivered on behalf of such entity and is a legal, valid and binding obligation of such entity; or (iii) if executing this
Agreement in a representative or fiduciary capacity, represents that it has full power and authority to execute and deliver this Agreement in such capacity and on behalf of the subscribing individual, ward, partnership, trust, estate, corporation,
or limited liability company or partnership, or other entity for whom the Stockholder is executing this Agreement, and such individual, partnership, ward, trust, estate, corporation, or limited liability company or partnership, or other entity has
full right and power to perform pursuant to this Agreement and represents that this Agreement constitutes a legal, valid and binding obligation of such entity. This Agreement has been duly executed and delivered by each Stockholder and (assuming the
due authorization, execution and delivery by the Company) constitutes a valid and binding obligation of such Stockholder, enforceable against such Stockholder in accordance with its terms, except to the extent enforcement is limited by bankruptcy,
insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors’ rights and by general equitable principles. 

Section 4.2 Ownership of Shares. As of the date hereof, each Stockholder is the lawful owner of the Voting Shares owned by such
Stockholder and has the sole power to vote or cause to be voted such shares or shares power to vote or cause to be voted such shares solely with one or more other persons. Each Stockholder has good and valid title to the Voting Shares owned by each
Stockholder, free and clear of any and all pledges, mortgages, liens, charges, proxies, voting agreements, encumbrances, adverse claims, options, security interests and demands of any nature or kind whatsoever, other than (i) those created by
this Agreement, or (ii) those existing under applicable securities laws. 
 Section 4.3 No Conflicts. (a) No
authorization, consent or approval of any other person is necessary for the execution of this Agreement by each Stockholder and (b) none of the execution and delivery of this Agreement by each Stockholder, the consummation by each Stockholder
of the transactions contemplated hereby or compliance by each Stockholder with any of the provisions hereof shall (i) result in, or give rise to, a violation or breach of or a default under any of the terms of any material contract,
understanding, agreement or other instrument or obligation to which each Stockholder is a party or by which each Stockholder or any of the Subject Shares or its assets may be bound or (ii) violate any applicable order, writ, injunction, decree,
judgment, statute, rule or regulation, except for any of the foregoing as would not reasonably be expected to materially impair each Stockholder’s ability to perform his obligations under this Agreement. 

  
 -4- 

 ARTICLE V  

REPRESENTATIONS AND WARRANTIES OF THE COMPANY 

The Company hereby represents and warrants to each Stockholder as follows: 

Section 5.1 Due Organization, etc. The Company is a Delaware corporation duly organized and validly existing under the laws of
Delaware. The Company has all necessary corporate power and authority to execute and deliver this Agreement and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement and the consummation of the transactions
contemplated hereby by the Company have been duly authorized by all necessary corporate action on the part of the Company. This Agreement has been duly executed and delivered by the Company and (assuming the due authorization, execution and delivery
by each Stockholder) constitutes a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except to the extent enforcement is limited by bankruptcy, insolvency, fraudulent transfer, reorganization,
moratorium and similar laws of general applicability relating to or affecting creditors’ rights and by general equitable principles. 

Section 5.2 No Conflicts. (a) No authorization, consent or approval of any other person is necessary for the execution of
this Agreement by the Company and (b) none of the execution and delivery of this Agreement by the Company, the consummation by the Company of the transactions contemplated hereby or compliance by the Company with any of the provisions hereof
shall (i) conflict with or result in any breach of the organizational documents of the Company, (ii) result in, or give rise to, a violation or breach of or a default under any of the terms of any material contract, understanding,
agreement or other instrument or obligation to which the Company is a party or by which the Company or any of its assets may be bound or (iii) violate any applicable order, writ, injunction, decree, judgment, statute, rule or regulation, except
for any of the foregoing as would not reasonably be expected to materially impair the Company’s ability to perform its obligations under this Agreement. 

ARTICLE VI  
 TERMINATION

 Section 6.1 Termination. This Agreement shall automatically terminate, and neither the Company nor the Stockholders shall
have any rights or obligations hereunder and this Agreement shall become null and void and have no effect upon the earliest to occur of: (a) the approval of the holders of at least 90% of the Subject Shares (which percentage shall take into
account any Subject Shares owned by a Stockholder that are not eligible to vote pursuant to any limitations on voting under the terms of the Series B Shares), (b) the closing of a firm commitment underwritten public offering of the
Company’s shares of Common Stock resulting in gross proceeds of at least $20 million or (iii) three years from the Effective Date. The termination of this Agreement shall not prevent either party from seeking any remedies (at law or in
equity) against the other party or relieve any party from liability for such party’s willful and material breach of any terms of this Agreement. Notwithstanding anything to the contrary herein, (i) the provisions of Article VII
shall survive the termination of this Agreement and (ii) if a Stockholder effectuates a sale, transfer or other disposition of its Subject Shares to a party that is not a Stockholder during the Voting Period, the transferee shall not acquire
Subject Shares subject to the terms of this Agreement. 

  
 -5- 

 ARTICLE VII 

MISCELLANEOUS 

Section 7.1 Further Actions. Each of the parties hereto agrees to take any all actions and to do all things reasonably necessary
or appropriate to effectuate this Agreement. 
 Section 7.2 Amendments, Waivers, etc. This Agreement may not be amended,
changed, supplemented, waived or otherwise modified, except upon the execution and delivery of a written agreement executed by the holders of at least 75% of the Subject Shares. The failure of any party hereto to exercise any right, power or remedy
provided under this Agreement or otherwise available in respect hereof at law or in equity, or to insist upon compliance by any other party hereto with its obligations hereunder, and any custom or practice of the parties at variance with the terms
hereof shall not constitute a waiver by such party of its right to exercise any such or other right, power or remedy or to demand such compliance. 

Section 7.3 Notices. All notices or other communications which are required or permitted under this Agreement shall be in writing
and sufficient if delivered by hand, by facsimile transmission, by registered or certified mail, post pre-paid, or by courier or overnight carrier, to the persons at the addresses set forth below (or at such other address as may be provided
hereunder), and shall be deemed to have been delivered as of the date so delivered: 
  

			
	 If to the Company
  

Atrinsic, Inc.
 149 Fifth Avenue, Suite 500

New York, NY 10010
 Attn: Robert Ziroyan, President

Facsimile: 508.734.2177
 Email: rziroyan@protagenic.com
	  	 Copy to (which copy shall not constitute
 notice
hereunder):
  
 Meister Seelig & Fein LLP

125 Park Avenue, 7th Floor

New York, NY 10017
 Attn: Mark J. Seelig, Esq.

Facsimile: (646) 539-3655
 Email:
mjs@msf-law.com

 If to the Stockholders: 

To each Stockholder at the address set forth on the signature page hereto or at such other address as any party shall have furnished to the
other parties in writing. 
 Section 7.4 Headings. Headings of the Articles and Sections of this Agreement are for convenience
of the parties only, and shall be given no substantive or interpretive effect whatsoever. 
 Section 7.5 Severability. The
provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof. If any provision of this Agreement, or the

  
 -6- 

 
application of such provision to any person or any circumstance, is invalid or unenforceable (a) a suitable and equitable provision shall be substituted therefor in order to carry out, so
far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (b) the remainder of this Agreement and the application of such provision to other persons or circumstances shall not be affected by such
invalidity or unenforceability, nor shall such invalidity or unenforceability affect the validity or enforceability of such provision, or the application of such provision, in any other jurisdiction. 

Section 7.6 Entire Agreement; Assignment. This Agreement constitutes the entire agreement, and supersedes all other prior
agreements and understandings, both written and oral, between the parties, or any of them, with respect to the subject matter hereof. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any of the
parties hereto (whether by operation of law or otherwise) without the prior written consent of the other parties. Subject to the preceding two sentences, this Agreement will be binding upon, inure to the benefit of and be enforceable by the parties
hereto and their respective successors and permitted assigns. 
 Section 7.7 Parties in Interest. The Company and the
Stockholders hereby agree that their respective representations, warranties and covenants set forth herein are solely for the benefit of the other party hereto, in accordance with and subject to the terms of this Agreement, and this Agreement is not
intended to, and does not, confer upon any person other than the parties hereto any rights or remedies hereunder, including, without limitation, the right to rely upon the representations and warranties set forth herein. The representations and
warranties in this Agreement are the product of negotiations among the parties hereto and are for the sole benefit of the parties hereto. Any inaccuracies in such representations and warranties are subject to waiver by the parties hereto in
accordance with Section 7.2 without notice or liability to any other person. In some instances, the representations and warranties in this Agreement may represent an allocation among the parties hereto of risks associated with particular
matters regardless of the knowledge of any of the parties hereto. Consequently, persons other than the parties hereto may not rely upon the representations and warranties in this Agreement as characterizations of actual facts or circumstances as of
the date of this Agreement or as of any other date. 
 Section 7.8 Interpretation. When a reference is made in this Agreement to
an Article or Section, such reference shall be to an Article or Section of this Agreement unless otherwise indicated. Whenever the words “include,” or “including” are used in this Agreement, they shall be deemed to be followed by
the words “without limitation.” The words “hereof,” “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision
of this Agreement. All terms defined in this Agreement shall have the defined meanings when used in any certificate or other document made or delivered pursuant thereto unless otherwise defined therein. The definitions contained in this Agreement
are applicable to the singular as well as the plural forms of such terms and to the masculine as well as to the feminine and neuter genders of such term. Any agreement, instrument or statute defined or referred to herein or in any agreement or
instrument that is referred to herein means such agreement, instrument or statute as from time to time amended, modified or supplemented in accordance with the terms hereof, including (in the case 

  
 -7- 

 
of agreements or instruments) by waiver or consent and (in the case of statutes) by succession of comparable successor statutes and references to all attachments thereto and instruments
incorporated therein. References to a person are also to its permitted successors and assigns. Each of the parties has participated in the drafting and negotiation of this Agreement. If an ambiguity or question of intent or interpretation arises,
this Agreement must be construed as if drafted by all the parties and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of authorship of any of the provisions of this Agreement. 

Section 7.9 Governing Law. THIS AGREEMENT SHALL BE DEEMED TO BE MADE IN AND IN ALL RESPECTS SHALL BE INTERPRETED, CONSTRUED AND
GOVERNED BY AND IN ACCORDANCE WITH THE LAW OF THE STATE OF NEW YORK WITHOUT REGARD TO THE CONFLICTS OF LAW PRINCIPLES THEREOF. 

Section 7.10 Specific Performance. The parties acknowledge that any breach of this Agreement would give rise to irreparable harm
for which monetary damages would not be an adequate remedy and that, in addition to other rights or remedies, the parties shall be entitled to seek enforcement of any provision of this Agreement by a decree of specific performance and to temporary,
preliminary and permanent injunctive relief to prevent breaches or threatened breaches of any of the provisions of this Agreement, without the necessity of proving the inadequacy of monetary damages as a remedy. 

Section 7.11 Submission to Jurisdiction. The parties hereby irrevocably submit to the exclusive jurisdiction of the United States
District Court for the Southern District of New York located in the borough of Manhattan in the City of New York, or if such court does not have jurisdiction, the Supreme Court of the State of New York, New York County, for the purposes of any suit,
action or other proceeding arising out of this Agreement or any transaction contemplated hereby. Each of the parties hereto further agrees that service of any process, summons, notice or document by registered mail to such party’s respective
address set forth in Section 7.3 (or to such other address for notices as provided by such party pursuant to Section 7.3) or in any other manner permitted by law shall be effective service of process for any action, suit or
proceeding in New York with respect to any matters to which it has submitted to jurisdiction as set forth above in the immediately preceding sentence. Each of the parties hereto irrevocably and unconditionally waives any objection to the laying of
venue of any action, suit or proceeding arising out of this Agreement or the transactions contemplated hereby in (i) the United States District Court for the Southern District of New York or (ii) the Supreme Court of the State of New York,
New York County, and hereby further irrevocably and unconditionally waives and agrees not to please or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum. 

Section 7.12 Waiver of Jury Trial. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS
LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR
RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. 

  
 -8- 

 
EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT
OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (II) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (III) EACH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (IV) EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT
BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 7.12. 
 Section 7.13 Counterparts. This
Agreement may be executed in two or more counterparts (including by facsimile or electronic submission via .pdf file), each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument,
and shall become effective when one or more counterparts have been signed by each of the parties and delivered (including by facsimile or electronic submission via .pdf file) to the other parties. 

[Signature Pages Follow] 

  
 -9- 

 IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed as of
the day and year first above written. 
  

			
	ATRINSIC, INC.
		
	By:	 	 /s/ Garo H. Armen

	Name:	 	Garo H. Armen
	Title:	 	Chairman

 IN WITNESS WHEREOF, the undersigned have caused this Voting Agreement to be duly executed
as of the day and year first above written. 
 PROTAGENIC THERAPEUTICS, INC. STOCKHOLDERS 

 

					
			
	 /s/ Garo H. Armen

Garo H. Armen
  

Address:   c/o Atrinsic, Inc.

                  149 Fifth
Avenue, Suite 500

                  New York,
NY 10010
	 		 	 /s/ Garo H. Armen

Garo H. Armen IRA
  

Address:   c/o Atrinsic, Inc.

                  149 Fifth
Avenue, Suite 500

                  New York,
NY 10010

			
	 /s/ Gregory H. Ekizian

Gregory H. Ekizian
  

Address:   1902 South Ardsley Street,

                  Tampa
Florida 33629
	 		 	 /s/ Gregory H. Ekizian

Gregory H. Ekizian Revocable Trust
  

Address:   1902 South Ardsley Street,

                  Tampa
Florida 33629

			
	 /s/ Alexander Arrow

Alexander Arrow
  

Address:   c/o Atrinsic, Inc.

                  149 Fifth
Avenue, Suite 500

                  New York,
NY 10010
	 		 	 /s/ Mark Berg

Mark Berg
  

Address:   210 Circle Rd,

                  Syosset,
NY 11791

			
	 /s/ Mark Berg

Mark Berg IRA
  

Address:   210 Circle Rd,

                  Syosset,
NY 11791
	 		 	 /s/ Larry N. Feinberg

Larry N. Feinberg
  

Address:   808 North St.

                  Greenwich,
CT 06831

			
	 /s/ David A. Lovejoy

David A. Lovejoy
  

Address:   149 Baker St.

                  
Stouffville, Ontario, L4A 1K6

                  
Canada
	 		 	

 IN WITNESS WHEREOF, the undersigned have caused this Voting Agreement to be duly executed
as of the day and year first above written. 
  

			
	STRATEGIC BIO PARTNERS, LLC
		
	By:	 	  

	Name:	 	
	Title:EX-10.5

 Exhibit 10.5 

This INDEMNITY AGREEMENT, dated as of February 12, 2016 (this “Agreement”), among Atrinsic, Inc.
(“Atrinsic”), Strategic Bio Partners, LLC (the “Indemnitor”), Iroquois Master Fund Ltd. (“Iroquois Master”), Iroquois Capital Investment Group (“Iroquois Capital”), and Hudson Bay Master
Fund Ltd. and (“Hudson Bay” and together with Iroquois Master and Iroquois Capital, the “Guarantors”). 

RECITALS: 

WHEREAS, reference is made to that certain Agreement and Plan of Merger and Reorganization, dated as of the date hereof (the
“Merger Agreement”), among Atrinsic, Protagenic Acquisition Corp. and Protagenic Therapeutics, Inc.; 
 WHEREAS, as
an inducement to the parties’ willingness to consummate the transactions contemplated by the Merger Agreement, the Indemnitor has agreed to indemnify Atrinsic for certain matters as described below up to the aggregate amount set forth herein.

 NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties hereby agree as follows: 
 1. Definitions. All capitalized terms used herein (including the
preamble and recitals hereto) and not otherwise defined herein shall have the meanings ascribed thereto in the Merger Agreement. 
 2.
Indemnification. The Indemnitor hereby covenants and agrees, at its sole cost and expense, to assume liability and/or reimburse Atrinsic for the following: 
  

	 	(i)	amounts due the U.S. Treasury for failure to file Form 5471 for its tax years ended December 31, 2011, December 31, 2012 and June 30, 2014 (the “Tax Claim”); 

 

	 	(ii)	amounts due the New York State Workers’ Compensation Board for Atrinsic’s failure to carry required workers’ compensation insurance for the period from July 6, 2011 to May 10, 2012 pursuant to a
judgment signed July 10, 2012 (the “2012 Workers’ Compensation Claim”); 

  

	 	(iii)	amounts that may be due the New York State Workers’ Compensation Board pursuant to a judgment signed October 5, 2011 (the “2011 Workers’ Compensation Claim”); 

 

	 	(iv)	amounts Atrinsic is required to pay as a result of its subsidiaries that are being simultaneously spun-off pursuant a Subsidiaries Split-Off Agreement between Atrinsic and Quintel Holdings, Inc. (the “Subsidiaries
Claim”); and 

  

	 	(v)	amounts due to the New York State Department of State as a result of Atrinsic’s failure to file its biennial statements with the New York State Department of State and to maintain its good standing as a foreign
entity registered to do business in New York State (the “NY Good Standing Claim”, and together with (i), (ii), (iii) and (iv) the “Indemnified Liabilities”); 

 and any penalties or interest that may accrue thereon, provided that the aggregate amounts payable in the
aggregate by the Indemnitor hereunder shall not exceed $200,000.00 (the “Indemnification Limit”). 
 3. The Tax Claim, the 2012
Workers’ Compensation Claim and the 2011 Workers’ Compensation Claim. 
 (a) Within forty-five (45) days following the
Closing of the Merger, the Indemnitor agrees to either pay all amounts due with respect to the Tax Claim, the 2012 Workers Compensation Claim and the 2011 Workers’ Compensation Claim or to commence negotiations with the Internal Revenue Service
and the New York State Workers’ Compensation Board with respect to the respective Claim pursuant to the power of attorney granted to the Indemnitor pursuant to Section 5 below. 

(b) In the event the Indemnitor shall fail to pay all amounts due with respect to the Tax Claim, 2012 Worker’s Compensation Claim and the
2011 Workers’ Compensation Claim within the aforesaid forty-five (45) day period or shall fail to commence negotiations with the applicable Governmental Institution, as defined below, within said period, or shall terminate such
negotiation, then Atrinsic shall be free to settle the respective Claim on such terms as Atrinsic sees fit. Atrinsic shall give the Indemnitor a minimum of ten (10) days written notice of its intention to settle the Claim and the terms thereof.
Within seven (7) days following receipt of that notice, the Indemnitor shall pay to Atrinsic the amount payable with respect to the Claim to be settled, subject to the Indemnification Limit. 

(c) In the event the Tax Claim, 2012 Worker’s Compensation Claim and/or the 2011 Workers’ Compensation Claim is still outstanding
twelve (12) months following the date of this Agreement, Atrinsic shall be free to settle the respective claim on such terms as Atrinsic sees fit. Atrinsic shall give the Indemnitor a minimum of ten (10) days prior written notice of its
intention to settle the Claim and the terms thereof. Within seven (7) days following receipt of that notice, the Indemnitor shall pay to Atrinsic the amount payable with respect to the Claim to be settled, subject to the Indemnification Limit.

 4. The Subsidiaries Claim. 

(a) If any Subsidiaries Claim is asserted against Atrinsic or any of its officers, directors, employees, stockholders, agents, representatives
and affiliates, then Atrinsic shall notify the Indemnitor within 20 days after receipt of that claim (said notification being referred to as a “Claim Notice”) and give the Indemnitor a reasonable opportunity to review the
Subsidiaries Claim and to conduct any negotiations related thereto, to defend Atrinsic and/or to settle the Subsidiaries Claim. The expenses (including reasonable attorney’s fees) of all negotiations proceedings, lawsuits or settlements of such
Subsidiaries Claims shall be borne by the Indemnitor and shall be excluded for purposes of calculating the Indemnification Limit. 

  
 - 2 - 

 (b) In the event the Indemnitor shall (i) fail to pay the aforesaid Subsidiaries Claim,
(ii) fail to defend Atrinsic with respect to that Subsidiaries Claim, (iii) discontinue its defense, (iv) fail to commence negotiations with the respective Governmental Institution or (v) terminate such negotiations, then
Atrinsic shall be free to settle that Subsidiaries Claim on such terms as Atrinsic sees fit. Atrinsic shall give the Indemnitor a minimum of ten (10) days prior within notice of its intention to settle the Subsidiaries Claim and the terms
thereof. Written seven (7) days following receipt of that notice, the Indemnitor shall pay to Atrinsic the amount payable with respect to the Subsidiaries Claim to be settled, subject to the Indemnification Limit. 

5. Power of Attorney. Atrinsic hereby grants the Indemnitor an irrevocable power-of-attorney to negotiate and/or appeal on behalf of
Atrinsic the Indemnified Liabilities with the New York State Workers’ Compensation Board, the Internal Revenue Service, the Delaware Secretary of State and the New York Secretary of State or any other federal or state institution with
jurisdiction over the Indemnified Liabilities (“Governmental Institution”); provided that any proposed agreement or settlement to which a Governmental Institution has agreed in principal regarding the Indemnified Liabilities (a
“Proposed Settlement”) may only be entered into in and become binding with the written agreement of Atrinsic; further provided that if Atrinsic does not agree in writing to a Proposed Settlement, the amount that the Indemnitor would
be required to pay for the Claim to which the Proposed Settlement relates shall henceforth be limited to the lesser of (i) the dollar amount that would have been paid in the Proposed Settlement, or (ii) the Indemnification Limit. The
powers-of-attorney granted in this section shall expire on the earliest of the date (i) that is twelve (12) months from the date hereof, (ii) on which there are no Indemnified Liabilities outstanding or (iii) on which no power of
attorney granted hereunder is outstanding. The Indemnitor may terminate its power of attorney by providing notice of such termination in writing to Atrinsic. 

6. Guaranteed Obligations. 

(a) Guaranteed Obligations. Guarantors jointly and severally hereby irrevocably and unconditionally guaranty to Atrinsic the
indefeasible payment in full in cash and discharge, or other satisfaction and discharge, in full of the Guaranteed Obligations (as defined below). “Guaranteed Obligations” means, collectively, all of the present and future payment
and performance obligations of Indemnitor arising from the Indemnified Liabilities and, for avoidable of doubt, subject to the Indemnification Limit. 

(b) Waiver. Guarantors waive diligence, presentment, protest, notice of dishonor, notice of default by Indemnitor, demand for payment,
extension of time for payment, notice of acceptance of this Guaranty, and indulgences and notices of every kind. Guarantors waive any rights of subrogation, indemnity, reimbursement, and contribution which would otherwise be acquired by Guarantors
by reason of their payment of any part of the Guaranteed Obligations. 
 (c) Guarantors’ Representation and Warranty. Each
Guarantor represents and warrants to Buyer that such Guarantor expects to derive substantial benefits from the transactions contemplated by the Merger Agreement and the indemnification provided for herein. 

  
 - 3 - 

 (d) Enforcement. This is a continuing guaranty of payment and performance, not a guaranty
of collection. Atrinsic may enforce this Guaranty without first proceeding against Indemnitor or any other person, and without first pursuing any other right or remedy. This Guaranty remains enforceable regardless of any defenses based on failure of
consideration, breach of warranty, fraud, statute of frauds, bankruptcy, lack of legal capacity, statute of limitations, lender liability, accord and satisfaction, or usury that the Indemnitor may assert on the Indemnified Obligations. 

(e) Enforcement Expenses. Each Guarantor shall pay or reimburse Atrinsic for all reasonable costs, expenses and attorneys’ fees
paid or incurred by Atrinsic on all meritorious claims in endeavoring to collect and enforce the Guaranteed Obligations and in enforcing this Guaranty. 

(f) Alteration of Indemnified Obligations. No provision of this Guaranty shall be construed to amend the Indemnified Obligations or to
relieve Indemnitor of any obligations thereunder. 
 (g) No Duties Owed by Atrinsic. Each Guarantor acknowledges and agrees that
Atrinsic (a) has not made any representations or warranties with respect to, (b) does not assume any responsibility to such Guarantor for, and (c) has no duty to provide information to such Guarantor regarding, the enforceability of
any of the Guaranteed Obligations. Applicable Law; Venue. 
 (h) Valid and Binding Instrument. Each Guarantor hereby represents,
warrants and covenants that this Guaranty is a legal, valid and binding instrument, enforceable against it in accordance with its terms. 

7. Applicable Law; Venue 

(a) This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York without giving effect to
any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of laws of any jurisdictions other than those of the State of New York. 

(b) Each of the Parties (a) submits to the jurisdiction of any state or federal court sitting in the County of New York in the State of
New York in any action or proceeding arising out of or relating to this Agreement, (b) agrees that all claims in respect of such action or proceeding may be heard and determined in any such court, and (c) agrees not to bring any action or
proceeding arising out of or relating to this Agreement in any other court. Each of the Parties waives any defense of inconvenient forum to the maintenance of any action or proceeding so brought and waives any bond, surety or other security that
might be required of any other Party with respect thereto. The prevailing party in any action or proceeding brought to enforce the terms of this Agreement shall be entitled to reimbursement of it reasonable legal fees and expenses incurred in
connection with that action or proceeding. 

  
 - 4 - 

 8. Counterparts. This Agreement may be executed in any number of counterparts, each of
which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument. 

9. Effectiveness. This Agreement shall become effective upon the execution and delivery of a counterpart hereof by each of the parties
hereto, but in no event shall it become effective prior to the Merger Agreement. 
 10. Successors and Assigns. This Agreement shall
be binding upon and inure to the benefit of the parties hereto, Atrinsic and their respective successors and assigns including all persons who become bound to this Agreement. Neither Iroquois Master, Iroquois Capital, nor Hudson Bay shall, without
the prior written consent of the other, assign any right, duty or obligation hereunder. 
 11. Severability. In case any provision in
or obligation hereunder shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in
any way be affected or impaired thereby. 
 12. Termination. This Agreement shall terminate upon the earlier of (a) the date on
which there are no Indemnified Liabilities outstanding or, in the case of the Subsidiaries Claim, potential claims outstanding, or (b) six (6) years from the date of the Closing. 

13. Headings. Section headings herein are included herein for convenience of reference only and shall not constitute a part hereof for
any other purpose or be given any substantive effect. 
 [Signature pages to follow] 

  
 - 5 - 

 IN WITNESS WHEREOF, Atrinsic, Iroquois Master, Iroquois Capital, and Hudson Bay have
caused this Indemnity Agreement to be duly executed and delivered by their respective officers thereunto duly authorized as of the date first written above. 

 

					
		 	ATRINSIC, INC.
			
		 	By:	 	 /s/ Edward Gildea

		 	Name:	 	Edward Gildea
		 	Title:	 	Chief Executive Officer
	
	STRATEGIC BIO PARTNERS, LLC
		
	By:	 	  

	Name:	 		 	
	Title:	 		 	
	
	GUARANTORS
		
		 	IROQUOIS MASTER FUND LTD.
			
		 	By:	 	  

		 	Name:	 	Joshua Silverman
		 	Title:	 	Authorized Signatory
		
		 	 IROQUOIS CAPITAL

INVESTMENT GROUP

			
		 	By:	 	  

		 	Name:	 	Joshua Silverman
		 	Title:	 	Authorized Signatory
		
		 	 HUDSON BAY MASTER FUND LTD.

			
		 	By:	 	  

		 	Name:	 	
		 	Title:	 	Authorized Signatory

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}]]